Resveratrol as MDR reversion molecule in breast cancer: An overview.
Breast cancer is the most common cause of cancer mortality among women worldwide; therefore, a strategy to defeat breast cancer is an extremely important medical issue. One of the major challenges in this regard is multidrug resistance (MDR). Resveratrol, a well-known phytoestrogen, may be helpful as part of an overall strategy to defeat breast cancer. The mixed agonist and antagonist role of resveratrol for the estrogen receptor makes it a controversial but interesting molecule in cancer therapy, especially in hormone dependent cancers. Several in vitro investigations have suggested that resveratrol can reverse multidrug resistance. However, poor bioavailability of resveratrol is a potential limitation for resveratrol treatment and cancer outcome in vivo. Fortunately, combination therapy with other selected compounds improves resveratrol's bioavailability and/or a delay in its metabolism. This review summaries the available published literature dealing with the effects of resveratrol on multidrug resistance in cancer and more specifically, breast cancer.
Biotechnology Research Center, School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran.
Nafiseh Sadat
NS
Alamolhodaei
Department of Forensic Sciences and Toxicology, Faculty of Medicine, University of Crete, Heraklion 71003, Greece.
Aristidis M
AM
Tsatsakis
Pharmaceutical Research Center, Department of Pharmaceutical Biotechnology, School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran.
Mohammad
M
Ramezani
Harvard University, Cambridge, MA USA and Michigan State University, East Lansing, MI, USA.
A Wallace
AW
Hayes
Pharmaceutical Research Center, Pharmacy School, Mashhad University of Medical Sciences, Mashhad, Iran. Electronic address: karimig@mums.ac.ir.
Gholamreza
G
Karimi
D000818:Animals; D000972:Antineoplastic Agents, Phytogenic / Q000494:pharmacology*; D017209:Apoptosis / Q000187:drug effects; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology; D004260:DNA Repair / Q000187:drug effects; D018432:Drug Resistance, Multiple / Q000187:drug effects; D019008:Drug Resistance, Neoplasm / Q000187:drug effects*; D020847:Estrogen Receptor Modulators / Q000494:pharmacology; D005260:Female; D006801:Humans; D008658:Inactivation, Metabolic; D048789:Phytoestrogens / Q000494:pharmacology; D000077185:Resveratrol; D013267:Stilbenes / Q000737:chemistry / Q000494:pharmacology*
D000972:Antineoplastic Agents, Phytogenic; D020847:Estrogen Receptor Modulators; D048789:Phytoestrogens; D013267:Stilbenes; D000077185:Resveratrol
Breast cancer; Daidzein (PubChem CID: 5281708); Daunorubicin (PubChem CID: 30323); Multidrug resistance; Paclitaxel (PubChem CID: 36314); Phytoestrogens; Resveratrol; Tamoxifen (PubChem CID: 2733526); cis-resveratrol (PubChem CID: 1548910); doxorubicin (PubChem CID: 31703); trans-resveratrol (PubChem CID: 445154)